Denmark · Delayed Price · Currency is DKK Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of DKK 1.25 trillion. The enterprise value is 1.35 trillion.
| Market Cap | 1.25T |
| Enterprise Value | 1.35T |
Important Dates
The last earnings date was Wednesday, February 4, 2026.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Mar 27, 2026 |
Share Statistics
Novo Nordisk has 4.44 billion shares outstanding. The number of shares has decreased by -0.34% in one year.
| Current Share Class | 3.37B |
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | -0.34% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 27.97% |
| Float | 3.19B |
Valuation Ratios
The trailing PE ratio is 12.19 and the forward PE ratio is 13.29. Novo Nordisk's PEG ratio is 1.83.
| PE Ratio | 12.19 |
| Forward PE | 13.29 |
| PS Ratio | 4.04 |
| PB Ratio | 6.43 |
| P/TBV Ratio | 19.49 |
| P/FCF Ratio | 21.15 |
| P/OCF Ratio | 10.47 |
| PEG Ratio | 1.83 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.72, with an EV/FCF ratio of 22.91.
| EV / Earnings | 13.19 |
| EV / Sales | 4.37 |
| EV / EBITDA | 8.72 |
| EV / EBIT | 9.61 |
| EV / FCF | 22.91 |
Financial Position
The company has a current ratio of 0.80, with a Debt / Equity ratio of 0.67.
| Current Ratio | 0.80 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 0.85 |
| Debt / FCF | 2.22 |
| Interest Coverage | 33.42 |
Financial Efficiency
Return on equity (ROE) is 60.70% and return on invested capital (ROIC) is 41.13%.
| Return on Equity (ROE) | 60.70% |
| Return on Assets (ROA) | 17.43% |
| Return on Invested Capital (ROIC) | 41.13% |
| Return on Capital Employed (ROCE) | 42.97% |
| Weighted Average Cost of Capital (WACC) | 6.09% |
| Revenue Per Employee | 4.47M |
| Profits Per Employee | 1.48M |
| Employee Count | 69,505 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.20 |
Taxes
In the past 12 months, Novo Nordisk has paid 28.11 billion in taxes.
| Income Tax | 28.11B |
| Effective Tax Rate | 21.53% |
Stock Price Statistics
The stock price has decreased by -52.64% in the last 52 weeks. The beta is 0.40, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -52.64% |
| 50-Day Moving Average | 339.81 |
| 200-Day Moving Average | 377.65 |
| Relative Strength Index (RSI) | 27.63 |
| Average Volume (20 Days) | 9,093,903 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novo Nordisk had revenue of DKK 309.06 billion and earned 102.43 billion in profits. Earnings per share was 23.03.
| Revenue | 309.06B |
| Gross Profit | 254.69B |
| Operating Income | 140.62B |
| Pretax Income | 130.54B |
| Net Income | 102.43B |
| EBITDA | 153.30B |
| EBIT | 140.62B |
| Earnings Per Share (EPS) | 23.03 |
Balance Sheet
The company has 26.96 billion in cash and 130.96 billion in debt, with a net cash position of -104.00 billion or -23.40 per share.
| Cash & Cash Equivalents | 26.96B |
| Total Debt | 130.96B |
| Net Cash | -104.00B |
| Net Cash Per Share | -23.40 |
| Equity (Book Value) | 194.05B |
| Book Value Per Share | 43.66 |
| Working Capital | -43.21B |
Cash Flow
In the last 12 months, operating cash flow was 119.10 billion and capital expenditures -60.14 billion, giving a free cash flow of 58.96 billion.
| Operating Cash Flow | 119.10B |
| Capital Expenditures | -60.14B |
| Free Cash Flow | 58.96B |
| FCF Per Share | 13.27 |
Margins
Gross margin is 82.41%, with operating and profit margins of 45.50% and 33.14%.
| Gross Margin | 82.41% |
| Operating Margin | 45.50% |
| Pretax Margin | 42.24% |
| Profit Margin | 33.14% |
| EBITDA Margin | 49.60% |
| EBIT Margin | 45.50% |
| FCF Margin | 19.08% |
Dividends & Yields
This stock pays an annual dividend of 11.70, which amounts to a dividend yield of 3.84%.
| Dividend Per Share | 11.70 |
| Dividend Yield | 3.84% |
| Dividend Growth (YoY) | 2.63% |
| Years of Dividend Growth | 8 |
| Payout Ratio | 50.53% |
| Buyback Yield | 0.34% |
| Shareholder Yield | 4.18% |
| Earnings Yield | 8.21% |
| FCF Yield | 4.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 13, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Sep 13, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Novo Nordisk has an Altman Z-Score of 5.15 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.15 |
| Piotroski F-Score | 5 |